Search Results - "Lipscomb, John C."

Human health effects of trichloroethylene: key findings and scientific issues by Chiu, Weihsueh A, Jinot, Jennifer, Scott, Cheryl Siegel, Makris, Susan L, Cooper, Glinda S, Dzubow, Rebecca C, Bale, Ambuja S, Evans, Marina V, Guyton, Kathryn Z, Keshava, Nagalakshmi, Lipscomb, John C, Barone, Jr, Stanley, Fox, John F, Gwinn, Maureen R, Schaum, John, Caldwell, Jane C

“…In support of the Integrated Risk Information System (IRIS), the U.S. Environmental Protection Agency (EPA) completed a toxicological review of…”
Get full text

Differences between Human and Rat Intestinal and Hepatic Bisphenol A Glucuronidation and the Influence of Alamethicin on In Vitro Kinetic Measurements by MAZUR, Christopher S, KENNEKE, John F, HESS-WILSON, Janet K, LIPSCOMB, John C

“…The extent to which membrane-disrupting agents, such as alamethicin, may alter cofactor transport and influence in vitro kinetic measurements of…”
Get full text

Putative Mechanisms of Environmental Chemical–Induced Steatosis by Kaiser, J. Phillip, Lipscomb, John C., Wesselkamper, Scott C.

“…Liver disease is a major health issue characterized by several pathological changes, with steatosis (fatty liver) representing a common initial step in its…”
Get full text

Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice by Sasso, Alan F, Schlosser, Paul M, Kedderis, Gregory L, Genter, Mary Beth, Snawder, John E, Li, Zheng, Rieth, Susan, Lipscomb, John C

“…Physiologically based pharmacokinetic (PBPK) models are tools for interpreting toxicological data and extrapolating observations across species and route of…”
Get full text

Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment by Meek, M.E. (Bette), Barton, Hugh A., Bessems, Jos G., Lipscomb, John C., Krishnan, Kannan

“…•WHO IPCS has released a guidance document on PBPK modeling in risk assessment.•Communication between modelers and risk assessors is key to regulatory use of…”
Get full text

Purpose-Driven Risk Assessment by Lipscomb, John C.

“…Chemical exposures are routine; some are controlled, some are not. Whether an exposure should be controlled depends on the acceptability of the consequences of…”
Get full text

Evaluating risk, exposure, and detection capabilities for chemical threats in water by Pfohl, Marisa, Silvestri, Erin, Lipscomb, John C., Snyder, Emily, Willison, Stuart

“…The unexpected release of chemicals into the environment requires estimation of human health risks, followed by risk management decisions. When environmental…”
Get full text

Corrigendum to ’Comparison of In Vivo Derived and Scaled In Vitro Metabolic Rate Constants for Several Volatile Organic Compounds (VOCs)’ [toxicology in vitro 68 (2020) start page–end page] by Kenyon, Elaina M., Eklund, Christopher, Pegram, Rex A., Lipscomb, John C.

Get full text

Comparison of in vivo derived and scaled in vitro metabolic rate constants for several volatile organic compounds (VOCs) by Kenyon, Elaina M., Eklund, Christopher, Pegram, Rex A., Lipscomb, John C.

“…Metabolic rate parameters estimation using in vitro data is necessary due to numbers of chemicals for which data are needed, trend towards minimizing…”
Get full text

In vitro measurements of metabolism for application in pharmacokinetic modeling by Lipscomb, John C, Poet, Torka S

“…Human risk and exposure assessments require dosimetry information. Species-specific tissue dose response will be driven by physiological and biochemical…”
Get full text

Gaining acceptance for the use of in vitro toxicity assays and QIVIVE in regulatory risk assessment by Meek, M.E. (Bette), Lipscomb, John C

“…Abstract Testing strategies are anticipated to increasingly rely on in vitro data as a basis to characterize early steps or key events in toxicity at relevant…”
Get full text

The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM) by Kenyon, Elaina M, Lipscomb, John C, Pegram, Rex A, George, Barbara J, Hines, Ronald N

“…Abstract Biotransformation rates extrapolated from in vitro data are used increasingly in human physiologically based pharmacokinetic (PBPK) models. This…”
Get full text

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver by Barter, Zoe E, Bayliss, Martin K, Beaune, Philip H, Boobis, Alan R, Carlile, David J, Edwards, Robert J, Houston, J Brian, Lake, Brian G, Lipscomb, John C, Pelkonen, Olavi R, Tucker, Geoffrey T, Rostami-Hodjegan, Amin

“…Reported predictions of human in vivo hepatic clearance from in vitro data have used a variety of values for the scaling factors human microsomal protein…”
Get more information

FutureTox III: Bridges for Translation by Juberg, Daland R, Knudsen, Thomas B, Sander, Miriam, Beck, Nancy B, Faustman, Elaine M, Mendrick, Donna L, Fowle, 3rd, John R, Hartung, Thomas, Tice, Raymond R, Lemazurier, Emmanuel, Becker, Richard A, Fitzpatrick, Suzanne Compton, Daston, George P, Harrill, Alison, Hines, Ronald N, Keller, Douglas A, Lipscomb, John C, Watson, David, Bahadori, Tina, Crofton, Kevin M

“…Future Tox III, a Society of Toxicology Contemporary Concepts in Toxicology workshop, was held in November 2015. Building upon Future Tox I and II, Future Tox…”
Get full text

Identification of developmentally toxic drinking water disinfection byproducts and evaluation of data relevant to mode of action by Colman, Joan, Rice, Glenn E., Wright, J. Michael, Hunter, E. Sidney, Teuschler, Linda K., Lipscomb, John C., Hertzberg, Richard C., Simmons, Jane Ellen, Fransen, Margaret, Osier, Mark, Narotsky, Michael G.

“…Reactions between chemicals used to disinfect drinking water and compounds present in source waters produce chemical mixtures containing hundreds of…”
Get full text

Evaluation of physiologically based pharmacokinetic models for use in risk assessment by Chiu, Weihsueh A., Barton, Hugh A., DeWoskin, Robert S., Schlosser, Paul, Thompson, Chad M., Sonawane, Babasaheb, Lipscomb, John C., Krishnan, Kannan

“…Physiologically based pharmacokinetic (PBPK) models are sophisticated dosimetry models that offer great flexibility in modeling exposure scenarios for which…”
Get full text

Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment by Lipscomb, John C, Haddad, Sami, Poet, Torka, Krishnan, Kannan

“…Physiologically-based pharmacokinetic (PBPK) modeling offers a scientifically-sound framework for integrating mechanistic data on absorption, distribution,…”
Get more information

The impact of variation in scaling factors on the estimation of internal dose metrics: a case study using bromodichloromethane (BDCM) by Kenyon, Elaina M., Eklund, Christopher, Lipscomb, John C., Pegram, Rex A.

“…A rate for hepatic metabolism (V max ) determined in vitro must be scaled for in vivo use in a physiologically based pharmacokinetic (PBPK) model. This…”
Get full text

Metabolism of Trichloroethylene by Lash, Lawrence H., Fisher, Jeffrey W., Lipscomb, John C., Parker, Jean C.

“…A major focus in the study of metabolism and disposition of trichloroethylene (TCE) is to identify metabolites that can be used reliably to assess flux through…”
Get full text

Correlating in vitro data to in vivo findings for risk assessment by Bale, Ambuja S, Kenyon, Elaina, Flynn, Thomas J, Lipscomb, John C, Mendrick, Donna L, Hartung, Thomas, Patton, Geoffrey W

“…A special session at the Toxicology and Risk Assessment Conference in Cincinnati, OH, USA in May, 2012 presented approaches expanding upon current uses of in…”
Get full text